Benign Prostatic Hyperplasia Therapeutics Analysis, Clinical Trials and Developments

Press Release

Benign prostatic hyperplasia therapeutics currently exhibits a proliferating pipeline with 15+ therapeutic candidates.

BPH can be identified as enlargement of prostate gland, a condition affects majority of male population. It is non-cancerous and goes through two main growth periods as a man age. The first phase begins in puberty, when the size of prostate becomes double. The second phase of prostate growth normally begins in the second decade of life. It is observed that men with a family history of BPH and chronic diseases such as heart disease, obesity, and diabetes are at higher risk of developing BPH. The condition thickens bladder wall, and eventually the bladder may weaken and lose the ability to empty completely. BPH is also associated with complications of urinary tract infection, bladder stones, kidney damage, and constant urge to urinate. The root cause of the disease remains unknown; however, increased level of estrogen is a suspected reason for the occurrence of this disease.

Request for sample copy of this report at:

As of 2018, there were eight marketed products for BPH such as Uroxatral, Cardura, Flomax, Proscar, Avodart, Cialis, Hytrin, and Rapaflo. Sales of these drugs and emergence of products in pipeline are expected to boost the growth of the market in coming years.

Moreover, Sanofi, Abbott Laboratories, Pfizer Inc., Astellas Pharma Inc., Eli Lilly and Company, Merck & Co. Inc., Nymox Pharmaceutical Corporation, GlaxoSmithKline plc, Allergan plc, Veru Inc., Urovant Sciences Inc., and Caremark Limited are some of the key players involved in the development of therapeutic agents for BPH.

BPH Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

This post was originally published on Financial Sector

Comments are closed.